Novartis pharmaceutical approved hypertension indications
Novartis pharmaceutical announced that the State Drug Administration approved nuoxintol on June 1 ®（ Salkubatrol (valsartan) is used to treat essential hypertension. As norcintal ®（ Following the listing of indications for heart failure in 2017, the second indication approved in China, this approval marks the breakthrough of new drugs in the field of hypertension treatment in China for more than 10 years, and is expected to lead the management mode of hypertension treatment from simple hypotension to the whole process risk control of cardiovascular events.
Sacubatrovalsartan is the world’s first angiotensin receptor enkephalinase inhibitor (Arni). The results of a phase III clinical study led by Professor Huo Yong, vice chairman of China Cardiovascular Health Alliance and the first hospital of Peking University, show that after 8 weeks of treatment, the antihypertensive effect of sakubatrovalsartan is significantly better than olmesartan (control drug), which has the best antihypertensive effect among ARB drugs, and can significantly improve the compliance rate of blood pressure. A total of 1438 Asian patients with mild to moderate essential hypertension aged 18 and over (sitting systolic blood pressure ≥ 140 to < 180 mm Hg) were included in the study, of which 85% were Chinese patients. In addition, many studies have also shown that whether the blood pressure level of patients with hypertension is high or low, whether they are combined with risk factors or heart and kidney damage, sacubatrovalsartan shows universal antihypertensive effect .
Hypertension is the primary risk factor for inducing cardiovascular events. As a large country of hypertension, China has 245 million adult patients with hypertension , but the standard rate of blood pressure is only 15.3% . The damage of heart, kidney, blood vessels and other organs caused by hypertension significantly increases the risk of cardiovascular death and keeps the disability and death rate related to hypertension high. Professor Huo Yong said: “the management of hypertension in China is facing multiple challenges, such as low compliance rate, high proportion of complications, aggravation of target organ damage and so on. In recent years, the treatment of hypertension began to focus on the treatment strategy based on hypotension, reducing the risk of cardiovascular events and improving the prognosis of patients. In terms of blood pressure reduction, sakubatrovalsartan shows the characteristics of large reduction, rapid onset and 24-hour pressure control. At the same time, it also shows superior protective effects on organs such as heart, kidney and blood vessels. It can block the chain of cardiovascular events in multiple ways and reduce the risk of cardiovascular events. The application of salkubatrol and Valsartan in the field of hypertension will further optimize the existing treatment scheme, which is of milestone significance to the management of hypertension. “